Alternatives & Reform

Animal testing will decline in some domains but persist in others. The key distinction: many New Approach Methodologies (NAMs) are validated for specific, well-bounded questions, while whole-organism complexity — multi-organ interaction, immune effects, chronic toxicity — remains harder to replace.

The 3Rs

The foundational framework for reform: Replace (use non-animal methods), Reduce (use fewer animals), Refine (minimize suffering). Embedded in EU Directive 2010/63/EU. Aspirational but not binding in the US.

Organ-on-a-Chip

Microphysiological systems that model human organ function on microengineered platforms:

• Liver-Chip validation — a blinded study of 870 chips across 27 drugs achieved 87% sensitivity and 100% specificity for predicting drug-induced liver injury (DILI)¹
• FDA acceptance — the FDA accepted the first organ-on-chip technology into its ISTAND pathway for DILI-related context of use²
• Market growth — valued at $153.8 million (2024), projected to reach $1.08 billion by 2031 (32% CAGR)³
• Key companies — Emulate (~17% market share), MIMETAS, CN Bio Innovations, TissUse (secured $25M Series C)
• Cost savings — estimated to reduce pharmaceutical R&D costs by 10-26%⁴

Computational Methods

• PBPK modeling (Physiologically Based Pharmacokinetics) — increasingly used in FDA-approved drug submissions (2019-2023), especially for drug-drug interaction assessment⁵
• AI/ML toxicity prediction — in silico models have outperformed animal models for predicting cardiac pro-arrhythmic toxicity
• ARPA-H contract — $31.7 million awarded to Deep Origin to build in silico models replacing animal testing

US law now defines "nonclinical test" to explicitly include in vitro, in silico, and in chemico tests.⁶

Legislative Reform

• FDA Modernization Act 2.0 (December 2022) — removed the 1938 mandate requiring animal testing. Allows alternatives. Does not ban animal testing.
• FDA Modernization Act 3.0 — passed the Senate unanimously in December 2025, further advancing the transition
• EPA — committed to eliminating mammalian testing for pesticides by 2035 (reinstated January 2026 by Administrator Zeldin after Biden administration had canceled the deadlines)⁷

Institutional Shifts

Three landmark changes in 2025:

• FDA announced a phase-out plan (April 2025) — animal studies to become "the exception rather than the norm" within 3-5 years, starting with monoclonal antibodies⁸
• NIH closed its last beagle laboratory (May 2025) — ending a 40-year program. White Coat Waste Project alleged NIH killed more than 2,133 beagles in septic shock experiments.⁹
• Congress directed the VA to end experiments on dogs, cats, and primates by 2026. VA dog usage had already declined from ~700 to 9 dogs over 19 years.¹⁰

What's NOT Being Replaced Yet

The main holdout is cardiovascular safety pharmacology — the ICH S7A/S7B framework that requires in vivo cardiac monitoring in a non-rodent species. No organ-on-chip or computational model has yet been validated as a replacement for the conscious telemetered beagle dog for QT/QTc assessment.

A HESI/FDA analysis of 150 drugs found that 28 of 43 drugs positive in clinical cardiac testing had no preclinical QT signal in dog studies — a ~65% false-negative rate.¹¹ This means the animal model is already performing poorly, but no alternative has demonstrated it can do better at regulatory-grade confidence.

Other areas where animal testing persists:
- Complex systemic toxicology (multi-organ effects over months)
- Reproductive and developmental toxicity
- Chronic neurotoxicity

The 5-10-20 Year Outlook

• Next 5 years — incremental reductions. More NAMs accepted for specific endpoints. Continued replacement of older tests (pyrogen, genotoxicity).
• Next 10 years — potential divergence point. If validation accelerates, NAMs could replace a large fraction of routine tests. If not, reductions come mainly from 3Rs measures.
• Next 20 years — replacement-by-segment, not total elimination. Many standardized hazard tests replaced. Some complex endpoints persist.¹²

Sources

1. 1.Liver-Chip performance evaluation. 870 chips, 27 drugs, blinded study. 87% sensitivity, 100% specificity for DILI.
2. 2.FDA ISTAND pathway. First organ-chip Letter of Intent accepted for DILI context of use (2024).
3. 3.Market analysis. Organ-on-a-chip market $153.8M (2024) → $1.079B by 2031.
4. 4.Drug Discovery Today expert survey. OOC technologies estimated to reduce pharma R&D costs 10-26%.
5. 5.Preclinical Rationale. PBPK use increasing in FDA-approved novel drugs 2019-2023.
6. 6.U.S. statutory definition of "nonclinical test" updated 2022 to include in vitro, in silico, in chemico.
7. 7.EPA press release, January 2026. Reinstated commitment to eliminate mammal testing by 2035.
8. 8.FDA roadmap, April 2025. Plan to reduce animal testing in preclinical safety studies.
9. 9.White Coat Waste Project / WJLA. NIH last beagle lab closed May 2025; >2,133 beagles alleged killed.
10. 10.Stars and Stripes, April 2024. Congress directed VA to end dog/cat/primate experiments by 2026.
11. 11.Preclinical Rationale. HESI/FDA QT analysis: 150 drugs, 43 TQT-positive, 28 with no preclinical signal.
12. 12.Future Outlook. Scenario-based projections for animal testing 2026-2046.